Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

04 Jan 2017

Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.

Cellectis SA of France hopes to begin clinical testing in the first half of this year with its gene edited product candidate in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This is the first IND filing for a gene edited allogeneic product candidate in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

05 May 2025

• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

02 May 2025

• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.